Cancer Stem Cells and Inhibition of Hedgehog Pathway Signaling in Advanced Pancreas Cancer: A Pilot Study of GDC-0449 in Combination With Gemcitabine
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Oct 2014
At a glance
- Drugs Gemcitabine (Primary) ; Vismodegib (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 01 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Jul 2013 Planned end date changed from 1 Jun 2016 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 31 Jan 2011 Planned End Date changed from 1 Jul 2011 to 1 Jun 2016 as reported by ClinicalTrials.gov. (NCT01195415 )